Cue Biopharma, Inc. (CUE): Price and Financial Metrics


Cue Biopharma, Inc. (CUE)

Today's Latest Price: $14.07 USD

0.35 (2.55%)

Updated Jan 22 4:00pm

Add CUE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CUE Stock Summary

  • Cue Biopharma Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 10.82% of US listed stocks.
  • Cue Biopharma Inc's stock had its IPO on January 2, 2018, making it an older stock than merely 9.32% of US equities in our set.
  • With a price/sales ratio of 111.42, Cue Biopharma Inc has a higher such ratio than 96.52% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Cue Biopharma Inc, a group of peers worth examining would be ZYME, ARVN, ACRS, MRKR, and ASMB.
  • CUE's SEC filings can be seen here. And to visit Cue Biopharma Inc's official web site, go to www.cuebiopharma.com.

CUE Stock Price Chart Interactive Chart >

Price chart for CUE

CUE Price/Volume Stats

Current price $14.07 52-week high $31.69
Prev. close $13.72 52-week low $9.30
Day low $13.27 Volume 263,700
Day high $14.16 Avg. volume 270,350
50-day MA $12.95 Dividend yield N/A
200-day MA $18.59 Market Cap 426.01M

Cue Biopharma, Inc. (CUE) Company Bio


Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company’s biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.


CUE Latest News Stream


Event/Time News Detail
Loading, please wait...

CUE Latest Social Stream


Loading social stream, please wait...

View Full CUE Social Stream

Latest CUE News From Around the Web

Below are the latest news stories about Cue Biopharma Inc that investors may wish to consider to help them evaluate CUE as an investment opportunity.

How Much Are Cue Biopharma, Inc. (NASDAQ:CUE) Insiders Spending On Buying Shares?

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

Yahoo | January 9, 2021

Is CUE A Good Stock To Buy Now?

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and successful investors’ positions as of the end of the third quarter. You can find articles about an individual hedge fund’s trades on numerous financial […]

Yahoo | December 16, 2020

News Flash: Analysts Just Made A Substantial Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Forecasts

Cue Biopharma, Inc. (NASDAQ:CUE) shareholders will have a reason to smile today, with the analysts making substantial...

Yahoo | November 25, 2020

Benzinga's Top Upgrades, Downgrades For November 24, 2020

Upgrades * B of A Securities upgraded the previous rating for O-I Glass Inc (NYSE: OI) from Neutral to Buy. The current stock performance of O-I Glass shows a 52-week-high of 15.64 and a 52-week-low of 4.305. Moreover, at the end of the last trading period, the closing price was at $11.86. * Goldman Sachs upgraded the previous rating for Nutanix Inc (NASDAQ: NTNX) from Sell to Neutral. Nutanix earned $0.44 in the first quarter, compared to $0.71 in the year-ago quarter. The stock has a 52-week-high of 37.86 and a 52-week-low of 11.31. At the end of the last trading period, Nutanix closed at $28.47. * For General Electric Co (NYSE: GE), Oppenheimer upgraded the previous rating of Perform to the current rating Outperform. General Electric earned $0.06 in the third quarter, compared to...

Yahoo | November 24, 2020

Cue Biopharma to Present at Upcoming Investor Conferences in November 2020

CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that it will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 and the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020. Cue Biopharma will provide an overview highlighting the Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, its expanding pipeline and anticipated milestones. The presentations will also include an update on the Company’s ongoing Phase 1 monotherapy dose escalation trial of CUE-101 including details pertaining to pat...

Yahoo | November 11, 2020

Read More 'CUE' Stories Here

CUE Price Returns

1-mo 7.73%
3-mo 10.18%
6-mo -26.87%
1-year -7.43%
3-year -9.81%
5-year N/A
YTD 12.47%
2020 -21.20%
2019 237.77%
2018 N/A
2017 N/A
2016 N/A

Continue Researching CUE

Here are a few links from around the web to help you further your research on Cue Biopharma Inc's stock as an investment opportunity:

Cue Biopharma Inc (CUE) Stock Price | Nasdaq
Cue Biopharma Inc (CUE) Stock Quote, History and News - Yahoo Finance
Cue Biopharma Inc (CUE) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7999 seconds.